Cargando…
Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240225/ https://www.ncbi.nlm.nih.gov/pubmed/28095797 http://dx.doi.org/10.1186/s12879-017-2196-0 |
_version_ | 1782496025522470912 |
---|---|
author | Martel-Laferrière, Valérie Nitulescu, Roy Cox, Joseph Cooper, Curtis Tyndall, Mark Rouleau, Danielle Walmsley, Sharon Wong, Leo Klein, Marina B. |
author_facet | Martel-Laferrière, Valérie Nitulescu, Roy Cox, Joseph Cooper, Curtis Tyndall, Mark Rouleau, Danielle Walmsley, Sharon Wong, Leo Klein, Marina B. |
author_sort | Martel-Laferrière, Valérie |
collection | PubMed |
description | BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multicenter prospective cohort study followed 1238 HIV-HCV co-infected persons every 6 months between 2003 and 2013. Data were analyzed from 573 patients with positive HCV RNA, not on HCV treatment, without significant liver fibrosis (AST-to-Platelet Ratio Index (APRI) <1.5) or history of end-stage liver disease at baseline, and having at least two study visits. Recent cocaine/crack use was defined as use within 6 months of cohort entry. Incidence rates of progression to significant fibrosis (APRI ≥ 1.5) were determined according to recent cocaine/crack use. Cox Proportional Hazards models were used to assess the association between time-updated cocaine/crack use and progression to APRI ≥ 1.5 adjusting for age, sex, HCV duration, baseline ln(APRI), and time-updated alcohol abuse, history of other drug use and CD4+ cell count. RESULTS: At baseline, 211 persons (37%) were recent cocaine/crack users and 501 (87%) ever used cocaine/crack. Recent users did not differ from non-recent users on gender, age, and CD4+ T-cell count. Over 1599 person-years of follow up (522 PY in recent users, 887 PY in previous users and 190 PY in never users),158 (28%) persons developed significant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4); 56 (27%) recent users (10.7/100 PY; 7.9–13.5), 81 (28%) previous users (9.1/100 PY; 7.1–11.1), and 21 (29%) never users (11.1/100 PY; 6.3–15.8). There was no association between ever having used or time-updated cocaine/crack use and progression to APRI ≥ 1.5 (adjusted HR (95%CI): 0.96 (0.58, 1.57) and 0.88;(0.63–1.25), respectively). CONCLUSIONS: We could not find evidence that cocaine/crack use is associated with progression to advanced liver fibrosis in our prospective study of HIV-HCV co-infected patients. |
format | Online Article Text |
id | pubmed-5240225 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-52402252017-01-19 Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study Martel-Laferrière, Valérie Nitulescu, Roy Cox, Joseph Cooper, Curtis Tyndall, Mark Rouleau, Danielle Walmsley, Sharon Wong, Leo Klein, Marina B. BMC Infect Dis Research Article BACKGROUND: Cocaine and crack use has been associated with HIV and HCV infections, but its consequences on HCV progression have not been well established. We analyzed the impact of cocaine/crack use on liver fibrosis progression in a cohort of HIV-HCV co-infected patients. METHODS: A Canadian multicenter prospective cohort study followed 1238 HIV-HCV co-infected persons every 6 months between 2003 and 2013. Data were analyzed from 573 patients with positive HCV RNA, not on HCV treatment, without significant liver fibrosis (AST-to-Platelet Ratio Index (APRI) <1.5) or history of end-stage liver disease at baseline, and having at least two study visits. Recent cocaine/crack use was defined as use within 6 months of cohort entry. Incidence rates of progression to significant fibrosis (APRI ≥ 1.5) were determined according to recent cocaine/crack use. Cox Proportional Hazards models were used to assess the association between time-updated cocaine/crack use and progression to APRI ≥ 1.5 adjusting for age, sex, HCV duration, baseline ln(APRI), and time-updated alcohol abuse, history of other drug use and CD4+ cell count. RESULTS: At baseline, 211 persons (37%) were recent cocaine/crack users and 501 (87%) ever used cocaine/crack. Recent users did not differ from non-recent users on gender, age, and CD4+ T-cell count. Over 1599 person-years of follow up (522 PY in recent users, 887 PY in previous users and 190 PY in never users),158 (28%) persons developed significant fibrosis (9.9/100 PY; 95% CI, 8.3–11.4); 56 (27%) recent users (10.7/100 PY; 7.9–13.5), 81 (28%) previous users (9.1/100 PY; 7.1–11.1), and 21 (29%) never users (11.1/100 PY; 6.3–15.8). There was no association between ever having used or time-updated cocaine/crack use and progression to APRI ≥ 1.5 (adjusted HR (95%CI): 0.96 (0.58, 1.57) and 0.88;(0.63–1.25), respectively). CONCLUSIONS: We could not find evidence that cocaine/crack use is associated with progression to advanced liver fibrosis in our prospective study of HIV-HCV co-infected patients. BioMed Central 2017-01-17 /pmc/articles/PMC5240225/ /pubmed/28095797 http://dx.doi.org/10.1186/s12879-017-2196-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Martel-Laferrière, Valérie Nitulescu, Roy Cox, Joseph Cooper, Curtis Tyndall, Mark Rouleau, Danielle Walmsley, Sharon Wong, Leo Klein, Marina B. Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title_full | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title_fullStr | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title_full_unstemmed | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title_short | Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study |
title_sort | cocaine/crack use is not associated with fibrosis progression measured by ast-to-platelet ratio index in hiv-hcv co-infected patients: a cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240225/ https://www.ncbi.nlm.nih.gov/pubmed/28095797 http://dx.doi.org/10.1186/s12879-017-2196-0 |
work_keys_str_mv | AT martellaferrierevalerie cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT nitulescuroy cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT coxjoseph cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT coopercurtis cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT tyndallmark cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT rouleaudanielle cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT walmsleysharon cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT wongleo cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT kleinmarinab cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy AT cocainecrackuseisnotassociatedwithfibrosisprogressionmeasuredbyasttoplateletratioindexinhivhcvcoinfectedpatientsacohortstudy |